Want to join the conversation?
$GILD said that for 1Q16 it reported non-GAAP diluted EPS of $3.03 vs. $2.94 in 1Q15. Total revenues were $7.8Bil, up 3% YoverY and down 8% sequentially. Product sales were $7.7Bil, an increase of 4% YoverY and down 9% sequentially. The company said that it sees strong uptick of its newer single-tablet regimens, including Genvoya.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.